Singapore's Biosensors revenues fall in Q4; Sun Pharma, AZ ink India distribution deal;

> Singapore-based Biosensors International said full year revenues for the quarter ended March 31 fell 7% to $75.9 million on lower licensing revenues and foreign exchange impacts. Release

> U.S./Australian drug discovery firm Novogen ($NVGN) said it raised nearly $17.7 million in a non-renounceable pro-rata rights issue that included local institutional investors picking up a shortfall on June 2. More

> Sun Pharmaceutical and AstraZeneca Pharma India ($AZN) inked an India distribution deal for the U.K.-based parent firm's Axcer (Brilinta) to treat acute coronary syndrome. Release

> China's Sanbao Ghana Pharmaceuticals has invested $15 million to expand production in Ghana. Report

> Australian Health Minister Sussan Ley appeared to back away from a proposed A$5 co-payment for patients, but Assistant Health Minister Fiona Nash has insisted "government policy hasn't changed." Report

> Qiagen ($QGEN) opened a principal office in Malaysia to serve its growing base of customers. Release

> Quintiles ($Q) opened a Greater China Regional Headquarters in Shanghai. Release

> Japan's Astellas Pharma presented initial Phase I and II data on ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory acute myeloid leukemia, at the American Society of Clinical Oncology's annual meeting in Chicago. Release

> Ruder Finn appointed John McInerney as director of healthcare digital strategy. Release

> Mundipharma awards research grant, renews sponsorship of International Primary Care Respiratory Group to aid support of respiratory physicians in Singapore and the region. Release

> Eisai Europe wins European Commission approval for Lenvima to treat adult patients with advanced or metastatic differentiated thyroid carcinoma. Release